Michael Dennis Price
Keine laufenden Positionen mehr
Profil
Michael Dennis Price served as Chief Financial Officer and Vice President at Noven Pharmaceuticals, Inc. from 2007 to 2016, Chief Financial Officer, Secretary, Treasurer, and Vice President at Teva Spanish Holdco, Inc. from 1992 to 2006, and Senior Executive at Carr Financial Group.
He also held positions as Vice President-Finance at Premiere Group, Inc. and Chief Financial Officer at Akcea Therapeutics, Inc. Mr. Price received his undergraduate degree from Auburn University and his MBA from Florida State University.
Ehemalige bekannte Positionen von Michael Dennis Price
Unternehmen | Position | Ende |
---|---|---|
NOVELION THERAPEUTICS INC. | Director of Finance/CFO | 16.01.2020 |
Noven Pharmaceuticals, Inc.
Noven Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Noven Pharmaceuticals, Inc. operates as a pharmaceutical company with transdermal expertise. It specializes in the research and development, manufacture, marketing, and sale of prescription pharmaceutical products. The company was founded in 1987 and is headquartered in Miami, FL. | Director of Finance/CFO | 01.01.2016 |
Teva Spanish Holdco, Inc.
Teva Spanish Holdco, Inc. Pharmaceuticals: MajorHealth Technology Teva Spanish Holdco, Inc. manufactures, markets, and distributes pharmaceutical products. It specializes in offering treatment for cardiovascular, gastrointestinal, infectious, and neurological diseases. The firm was founded in 1974, and is headquartered in Exeter, NH. | Director of Finance/CFO | 01.09.2006 |
AKCEA THERAPEUTICS, INC. | Director of Finance/CFO | - |
Premiere Group, Inc. | Director of Finance/CFO | - |
Ausbildung von Michael Dennis Price
Auburn University | Undergraduate Degree |
Florida State University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 6 |
---|---|
Noven Pharmaceuticals, Inc.
Noven Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Noven Pharmaceuticals, Inc. operates as a pharmaceutical company with transdermal expertise. It specializes in the research and development, manufacture, marketing, and sale of prescription pharmaceutical products. The company was founded in 1987 and is headquartered in Miami, FL. | Health Technology |
Teva Spanish Holdco, Inc.
Teva Spanish Holdco, Inc. Pharmaceuticals: MajorHealth Technology Teva Spanish Holdco, Inc. manufactures, markets, and distributes pharmaceutical products. It specializes in offering treatment for cardiovascular, gastrointestinal, infectious, and neurological diseases. The firm was founded in 1974, and is headquartered in Exeter, NH. | Health Technology |
Carr Financial Group | |
Premiere Group, Inc. | |
Akcea Therapeutics, Inc.
Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
Novelion Therapeutics, Inc.
Novelion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelion Therapeutics, Inc. engaged in the development and commercialization of pharmaceuitical products. It focused in providing new standards of care for individuals living with rare diseases. The company was founded on February 3, 1981 and was headquartered in Vancouver, Canada. | Health Technology |